Education
About Us
Working with TipRanks
Follow Us
Bausch + Lomb Corporation (BLCO)
NYSE:BLCO
BLCO Stock Chart & Stats
$18.41
$0.21(1.15%)
At close: 4:00 PM EST
$18.41
$0.21(1.15%)
Day’s Range― - ―
52-Week Range$10.45 - $18.92
Previous CloseN/A
Volume107.99K
Average Volume (3M)405.48K
Market Cap
$6.52B
Enterprise Value$11.48B
Total Cash (Recent Filing)$383.00M
Total Debt (Recent Filing)$5.37B
Price to Earnings (P/E)―
Beta0.90
Next Earnings
May 06, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.32
Shares Outstanding354,318,200
10 Day Avg. Volume391,487
30 Day Avg. Volume405,477
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)0.94
Price to Sales (P/S)1.18
P/FCF Ratio-91.56
Enterprise Value/Market Cap1.76
Enterprise Value/Revenue2.25
Enterprise Value/Gross Profit3.83
Enterprise Value/Ebitda20.07
Forecast
1Y Price Target
$18.60Price Target Upside1.03% Upside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)0.78
Revenue Forecast (FY)$5.43B
Bulls Say, Bears Say
Bulls Say
Guidance And Strategic PlanningManagement issued guidance above consensus and presented a long‑range plan with multi‑year financial targets, reinforced by an Investor Day outlining execution priorities.
Pharmaceutical Product MomentumCommercial adoption of MIEBO picked up pace and management raised peak sales expectations for the product while Xiidra is positioned for revenue growth and higher profitability after ending a low‑margin retail agreement.
Revenue And Segment GrowthRevenue expanded across Vision Care, Surgical, and Pharmaceuticals, with overall sales beating analyst expectations and contact lens demand strengthening in both the U.S. and China.
Bears Say
Corporate Separation UncertaintyUncertainty around the timing and completion of the parent company's separation creates an overhang and is cited as a key reason for cautious analyst ratings.
GAAP ProfitabilityThe company reported a GAAP net loss while adjusted results were profitable, leaving reported earnings affected by non‑operational items.
Margin PressureGross margin missed analyst expectations, indicating ongoing pressure on core profitability.
Bausch + Lomb Corporation News
BLCO FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
Bausch + Lomb Corporation lowest stock price was $10.45 and its highest was $18.91 in the past 12 months.
What is Bausch + Lomb Corporation’s market cap?
Bausch + Lomb Corporation’s market cap is $6.52B.
When is Bausch + Lomb Corporation’s upcoming earnings report date?
Bausch + Lomb Corporation’s upcoming earnings report date is May 06, 2026 which is in 63 days.
How were Bausch + Lomb Corporation’s earnings last quarter?
Bausch + Lomb Corporation released its earnings results on Feb 18, 2026. The company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.355 by -$0.035.
Is Bausch + Lomb Corporation overvalued?
According to Wall Street analysts Bausch + Lomb Corporation’s price is currently Undervalued.
Does Bausch + Lomb Corporation pay dividends?
Bausch + Lomb Corporation does not currently pay dividends.
What is Bausch + Lomb Corporation’s EPS estimate?
Bausch + Lomb Corporation’s EPS estimate is 0.06.
How many shares outstanding does Bausch + Lomb Corporation have?
Bausch + Lomb Corporation has 354,318,200 shares outstanding.
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Bausch + Lomb Corporation reported an EPS of $0.32 in its last earnings report, missing expectations of $0.355. Following the earnings report the stock price went down -0.338%.
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
Currently, no hedge funds are holding shares in BLCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bausch + Lomb Corporation Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$18.60 (1.03% Upside)
$18.60 (1.03% Upside)
Blogger Sentiment
Bullish
BLCO Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 82.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $416.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.00%
12-Months-Change
Fundamentals
Return on Equity
-4.69%
Trailing 12-Months
Asset Growth
2.35%
Trailing 12-Months
Company Description
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
BLCO Company Deck
BLCO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed materially positive operational and financial momentum: a record Q4 and full-year, strong top-line growth in key franchises (notably Miebo and contact lenses), significant EBITDA expansion and clear 2026 guidance that targets continued revenue growth and margin improvement. Progress on the pipeline (clinical wins, launches, CE filings) and improved cash-flow discipline further support a constructive outlook. The principal risks noted were the residual effects of the enVista recall, tariff impacts, elevated interest expense and a large external share float; these are meaningful but do not negate the company’s clear execution narrative and raised outlook. On balance, highlights substantially outweigh the lowlights.View all BLCO earnings summariesBLCO Stock 12 Month Forecast
Average Price Target
$18.60
▲(1.03% Upside)
Technical Analysis
Ownership Overview
0.60% Insiders
0.54% Mutual Funds
0.81% Other Institutional Investors
97.66% Public Companies and
Individual Investors